MarketPulse

biosimilar competition

3 articles
Investing.comInvesting.com··Chris Markoch

Gene-Editing Pioneers Emerge as M&A Targets Amid $300B Biotech Patent Cliff

Biotech M&A surges as $300B patent cliff looms by 2030. Three gene-editing firms positioned as acquisition targets offer varying risk profiles.
BMYCELGrMRKBEAMCRSP+1patent cliffCRISPR
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Biogen's Three-Decade Winning Streak Under Pressure as Biosimilars Loom

Biogen's three-decade outperformance is challenged by biosimilar competition and weak growth, though new Alzheimer's and rare disease drugs offer hope. Success requires flawless execution.
BIIBESAIYbiotechrevenue growth
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

AbbVie Stock Declines Despite Strong Quarterly Results and Pipeline Growth

AbbVie stock fell despite strong Q4 results and 10% revenue growth. Investors worry about Humira patent expiration, though new drugs Skyrizi and Rinvoq show promise.
ABBVearnings reportdividend stock